C11orf82 Polyclonal antibody

C11orf82 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 27754-1-AP

Print datasheet

Synonyms

noxin, Nitric oxide-inducible gene protein, DNA damage-induced apoptosis suppressor protein, DNA Damage Induced Apoptosis Suppressor, DDIAS



经过测试的应用

Positive WB detected inHepG2 cells, K-562 cells, NCI-H1299 cells

推荐稀释比

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

27754-1-AP targets C11orf82 in WB, ELISA applications and shows reactivity with human samples.

Tested Applications WB, ELISA Application Description
Tested Reactivity human
Immunogen C11orf82 fusion protein Ag26829 种属同源性预测
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Full Name chromosome 11 open reading frame 82
Synonyms noxin, Nitric oxide-inducible gene protein, DNA damage-induced apoptosis suppressor protein, DNA Damage Induced Apoptosis Suppressor, DDIAS
Observed Molecular Weight120 kDa
GenBank Accession NumberBC039268
Gene Symbol C11orf82
Gene ID (NCBI) 220042
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
UNIPROT IDQ8IXT1
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

DNA damage-induced apoptosis suppressor (DDIAS) is an oncogenic protein that is highly expressed in several cancers, including colorectal, lung, breast, and hepatocellular carcinoma (HCC), and stimulates cancer cell proliferation and cell cycle progression.DDIAS protects cancer cells from DNA damage reagents and tumor necrosis factor-associated apoptosis-inducing ligands (TRAILs) and positively regulates cancer cell invasion by stabilizing the β- catenin positively regulates cancer cell invasion. Therefore, DDIAS is considered as a potential therapeutic target for malignant lung cancer.

实验方案

Product Specific Protocols
WB protocol for C11orf82 antibody 27754-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols